| 进展期胃癌β-tubulinⅢ和survivin的表达及与多西紫杉醇耐药性关系 |
| 投稿时间：2011-03-16 修订日期：2011-03-31 点此下载全文 |
| 引用本文：郑维锷,原少斐,陈华,吴丽丽,张武,孙红雨,陈文俊.进展期胃癌β-tubulinⅢ和survivin的表达及与多西紫杉醇耐药性关系[J].医学研究杂志,2012,41(1):79-83 |
| DOI：
|
| 摘要点击次数: 1335 |
| 全文下载次数: 1062 |
|
| 基金项目:温州市科技计划项目（Y20100024） |
|
| 中文摘要:目的探讨进展期胃癌中β-tubulinⅢ和survivin的表达与多西紫杉醇化疗耐药性关系。方法回顾性分析74例接受多西紫杉醇化疗的晚期胃癌患者的临床病理资料。免疫组织化学法检测肿瘤标本β-tubulinⅢ和survivin蛋白的表达，并对疗效、不良反应进行分析。结果β-tubulinⅢ阳性表达率为37.8％(28/74)，survivin阳性表达率为58.1％(43/74)，均与性别、年龄及组织类型无关。化疗有效率(CR+PR)为54.10％，β-tubulinⅢ(+)的患者有效率低(32.14％)，β-tubulinⅢ(-)患者有效率高(69.57％)，差异有显著性(P<0.05)。Survivin (+)组的有效率为32.56％，低于survivin (-)组的67.74％，差异有显著性(P<0.05)。联合检测显示：β-tubulinⅢ(+)且survivin (+)组有效率为25.0％，中位疾病无进展期为4.1个月，1年、2年生存率分别为35.0%、15.0%，β-tubulinⅢ(-)且survivin (-)组有效率为73.91％，中位疾病无进展期为7.8个月，1年、2年生存率分别为56.5%、30.4%，差异均有显著性(P<0.05)。最常见的不良反应为骨髓抑制、消化道反应。结论β-tubulinⅢ和survivin高表达的进展期胃癌患者对多西紫杉醇化疗耐药。 |
| 中文关键词:胃癌 多西紫杉醇 β-微管蛋白Ⅲ |
| |
| SurvivinRelationship Between Expression of β-tubulinⅢ，Survivin and Drug Resistance to Docetaxel in Advanced Gastric Cancer |
|
|
| Abstract:ObjectiveTo investigate the relationship between the expression of β-tubulinⅢ，survivin protein and chemoresistance to docetaxel in advanced gastric cancer．MethodsSeventy-four patients of advanced gastric cancer treated with docetaxel were enrolled in this study and their tumor samples were collected retrospectively for analysis．The expression of β-tubulinⅢ，survivin protein in tumor samples was detected by the immunohistochemical methods．The data of therapeutical effect and toxicity were collected and analyzed．ResultsThe β-tubulinⅢ positive staining accounted for 37.8％(28/74)．The survivin positive staining accounted for 58.1％(43/74)．There was no correlation between β-tubulinⅢ，survivin positive expression and age，gender，pathological type．The response rate(CR+PR)was 54.10％．Patients with over-expression of β-tubulinⅢ had less response rate(32.14％ vs 69.57％) to docetaxel (P<005)．Patients with over-expression of survivin had less respeme rate(32.56％ vs 67.74％) to docetaxel (P<0.05)．Patients with over-expression of β-tubulinⅢ and survivin had also lower response rate(25.0％ vs 73.91％，P<0.05)．Patients with over-expression of β-tubulinⅢ and survivin had also lower the median time to progress and 1-and 2-year survival rates(4.1m vs 7.8 m，35.0% vs 56.5%，15.0% vs 30.4%, P<0.05)．The mainside-effects were myelosuppression and digestive apparatus toxicity.ConclusionOver-expression of β-tubulinⅢ，survivin in tumor cells was associated with resistance to docetaxel in patients with advanced gastric cancer receiving docetaxel-based chemotherapy． |
| keywords:Gastric cancer Docetaxel β-tubulinⅢ Survivin |
| 查看全文 查看/发表评论 下载PDF阅读器 |
